SCHEMBL6076718

SCHEMBL6076718

CON=Cc1ccc(F)cc1SC

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.34
GAA P10253 1/20 0.34
GRIN2D O15399 2/20 0.33
GRIN3B O60391 2/20 0.33
GRIN1 Q05586 2/20 0.33
GRIN2A Q12879 2/20 0.33
GRIN2B Q13224 2/20 0.33
GRIN2C Q14957 2/20 0.33
GRIN3A Q8TCU5 2/20 0.33
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
KDM4E B2RXH2 1/20 0.31
NFE2L2 Q16236 1/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
ADRA1D P25100 1/20 0.30
ADRA1A P35348 1/20 0.30
ADRA1B P35368 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077684 0.79 GRIN2D (0.51) SRCGAAGRIN2DGRIN3BGRIN1
SCHEMBL6077689 0.79 GRIN2D (0.51) SRCGAAGRIN2DGRIN3BGRIN1
SCHEMBL6448339 0.76 MAPT (0.39) SRCGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6448341 0.76 MAPT (0.39) SRCGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL14572070 0.75 ABCB1 (0.38) SRCGAAPOLBMAPTADRA2A
SCHEMBL13128154 0.75 NFE2L2 (0.47) SRCGAAGRIN2DGRIN3BGRIN1
SCHEMBL6877880 0.73 IDO1 (0.39) SRCGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6877878 0.73 IDO1 (0.39) SRCGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11131347 0.73 NFE2L2 (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL362934 0.73 ALDH1A1 (0.42) MAPTRAB9AKDM4ENFE2L2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF SRC 1543/4885GAA 379/4885GRIN2D 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.